• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Evoke Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/22/25 4:30:21 PM ET
    $EVOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVOK alert in real time by email
    8-K
    false000140370800014037082025-05-212025-05-21

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 21, 2025

     

     

    EVOKE PHARMA, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-36075

    20-8447886

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    420 Stevens Avenue, Suite 230

     

    Solana Beach, California

     

    92075

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 858 345-1494

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    EVOK

     

    The Nasdaq Stock Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    The Company held its Annual Meeting solely by means of remote communication through a live webcast on May 21, 2025, at 8:30 a.m., Pacific Time. There were represented at the Annual Meeting, by proxy, 960,070 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), out of a total number of 1,492,858 shares of Common Stock outstanding and entitled to vote at the Annual Meeting. The Company’s stockholders voted on the following three proposals at the Annual Meeting, casting their votes as described below.

    The following individuals, who were named as nominees in the Company’s definitive proxy statement relating to the Annual Meeting, were elected by the Company’s stockholders by a plurality of votes cast to serve a three-year term on the Company’s Board of Directors (the "Board") which will expire at the Company’s 2028 annual meeting of stockholders. Information on the vote relating to the director standing for election is set forth below:

     

    Proposal 1. – Election of Class III Directors.

     

    Nominee

     

    For

     

     

    Withheld

     

     

    Broker Non-Votes

     

     

    Mr. Malcolm R. Hill, Pharm.D.

     

     

    327,711

     

     

     

    128,684

     

     

     

    503,675

     

     

    Ms. Vickie W. Reed

     

     

    335,555

     

     

     

    120,840

     

     

     

    503,675

     

     

    Proposal 2. – Ratification of Appointment of BDO USA, P.C.

    Proposal 2 was to ratify the appointment of BDO USA, P.C., an independent registered public accounting firm, as the Company’s independent auditors for the year ending December 31, 2025. The proposal was approved.

    For

     

     

    Against

     

     

    Abstain

     

     

    935,706

     

     

     

    12,174

     

     

     

    12,190

     

    Proposal 3. – Advisory Vote on Executive Compensation.

    Proposal 3 was to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement. The proposal was approved.

    For

     

     

    Against

     

     

    Abstain

     

     

    Broker Non-Votes

     

     

    308,413

     

     

     

    144,621

     

     

     

    3,361

     

     

     

    503,675

     

    Proposal 4. – Frequency of Stockholder Vote on Executive Compensation.

    Proposal 4 was to approve, on an advisory basis, the frequency of holding future advisory votes on the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement. The “Three Years” alternative received the highest number of votes and is the stockholders’ recommendation, on an advisory basis, of the frequency of the stockholder vote on executive compensation. The Board determined to hold future advisory votes on executive compensation every three years based upon the stockholders’ recommendation.

    One Year

     

     

    Two Years

     

     

    Three Years

     

     

    Abstain

     

     

    Broker Non-Votes

     

     

     

    207,519

     

     

     

    871

     

     

     

    242,339

     

     

     

    5,666

     

     

     

    503,675

     

     

     

     

     

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    EVOKE PHARMA, INC.

     

     

     

     

    Date:

    May 22, 2025

    By:

    /s/ Matthew J. D'Onofrio

     

     

     

    Name: Matthew J. D'Onofrio
    Title: Chief Executive Officer and Director

     


    Get the next $EVOK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVOK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EVOK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for GIMOTI

      Submission status for EVOKE PHARMA INC's drug GIMOTI (SUPPL-1) with active ingredient METOCLOPRAMIDE HYDROCHLORIDE has changed to 'Approval' on 01/14/2021. Application Category: NDA, Application Number: 209388, Application Classification: Labeling

      1/15/21 5:10:35 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

      Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. "We're pleased to report continued strong revenue growth in the first quarter of 2025," said Matt D'Onofrio, Chief Executive Officer of Evoke Pharma, Inc. "Net product sales rose 77% year-over-year, underscoring the strengt

      5/13/25 4:05:56 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025

      SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced that a new abstract comparing the incidence of tardive dyskinesia (TD) in patients receiving continuous versus intermittent oral metoclopramide (OMCP) treatment has been accepted for presentation at Digestive Disease Week® (DDW) 2025, taking place May 3–6, 2025, in San Diego, CA. The analysis leverages real-world data from over 100 million U.S. patients and highlights differences in TD incidence rates and timing based on metoclopramide dosing patterns. "This

      4/28/25 8:30:48 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance Presented compelling healthcare resource utilization data on GIMOTI at key gastroenterology conferences, including an award-winning study on GLP-1 users with diabetic gastroparesis at ACG 2024 Conference call and webcast to be held today at 4:30 p.m. ET SOLANA BEACH, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatm

      3/13/25 4:02:27 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hill Malcolm R

      4 - Evoke Pharma Inc (0001403708) (Issuer)

      5/22/25 5:00:28 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Brady Todd C

      4 - Evoke Pharma Inc (0001403708) (Issuer)

      5/22/25 5:00:29 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Garner Cam L

      4 - Evoke Pharma Inc (0001403708) (Issuer)

      5/22/25 5:00:24 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    SEC Filings

    See more
    • Evoke Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Evoke Pharma Inc (0001403708) (Filer)

      5/22/25 4:30:21 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Evoke Pharma Inc.

      SCHEDULE 13G/A - Evoke Pharma Inc (0001403708) (Subject)

      5/15/25 3:51:53 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Evoke Pharma Inc.

      10-Q - Evoke Pharma Inc (0001403708) (Filer)

      5/13/25 4:20:20 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Evoke Pharma Inc.

      SC 13G/A - Evoke Pharma Inc (0001403708) (Subject)

      11/14/24 1:08:23 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evoke Pharma Inc.

      SC 13G/A - Evoke Pharma Inc (0001403708) (Subject)

      11/14/24 9:19:50 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Evoke Pharma Inc.

      SC 13D/A - Evoke Pharma Inc (0001403708) (Subject)

      11/6/24 4:31:54 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    Financials

    Live finance-specific insights

    See more
    • Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance Presented compelling healthcare resource utilization data on GIMOTI at key gastroenterology conferences, including an award-winning study on GLP-1 users with diabetic gastroparesis at ACG 2024 Conference call and webcast to be held today at 4:30 p.m. ET SOLANA BEACH, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatm

      3/13/25 4:02:27 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025

      SOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2024 on Thursday, March 13, 2025, after the market closes. Management will host a conference call and webcast with accompanying slides on Thursday, March 13, 2025, at 4:30 p.m. ET to discuss the results. The dial-in numbers for the conference call are (800) 267-6316 and (203) 518-9783 for international callers. The conference ID number is EVOKQ424.

      3/6/25 8:30:28 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

      GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year Strong cumulative prescriber growth, 45% year-over-year increase 52% year-over-year prescription fill increase; 39% increase since Q1 2024 Real-world data presented at ACG 2024 demonstrates that GIMOTI significantly enhanced outcomes for patients on GLP-1 therapy, marking it as a promising supportive care option compared to oral metoclopramide. SOLANA BEACH, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (met

      11/7/24 4:05:52 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVOK
    Leadership Updates

    Live Leadership Updates

    See more
    • Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors

      SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the second board member appointment by Nantahala Capital Management, reinforcing its continued confidence in Evoke's commercial strategy and growth potential. Mr. Pyszczymuka is a proven commercial leader with extensive experience in pharmaceutical sales, market access, and revenue growth. He currently serves as Chief Commer

      2/24/25 8:30:37 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors

      SOLANA BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, announced the appointment of Ben Smeal to serve on the Company's Board of Directors effective October 18, 2024.   This appointment fulfills a condition set as part of the company's most recent financing by Nantahala Capital Management. Mr. Smeal brings extensive experience in investment management and corporate governance. Before transitioning to full-time private investing, he held roles at Willett Advisors, the family office of Michael R. Bl

      10/22/24 8:30:15 AM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer

      SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that Matthew J. D'Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer's departure for personal reasons. Mr. D'Onofrio currently serves as President and Chief Operating Officer. "Working closely with Dave has been an absolute privilege," said Matt D'Onofrio, incoming Chief Executive Officer of Evoke Pharma. "His relentless leadership resulted in our company developing and launchi

      3/21/24 4:15:59 PM ET
      $EVOK
      Biotechnology: Pharmaceutical Preparations
      Health Care